Literature DB >> 10550013

STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription.

R Catlett-Falcone1, W S Dalton, R Jove.   

Abstract

Although the signal transducer and activator of transcription (STAT) proteins were originally discovered through the study of interferon-induced responses, a large number of cytokines and growth factors have been found to activate STATs. In addition to the fundamental role of STAT pathways in normal cell signaling, accumulating evidence is defining a critical role for STATs in oncogenesis. STAT family members are constitutively activated by various oncoproteins in transformed cells and are found activated in a wide variety of human tumors, including breast cancer and diverse blood malignancies. This review discusses recent progress in understanding how aberrant activation of STAT signaling pathways participates in malignant progression of human cancers. Current evidence indicates that one mechanism by which STATs contribute to oncogenesis involves prevention of programmed cell death, or apoptosis, thereby conferring a survival advantage and, potentially, resistance to chemotherapy. These advances identify STATs as novel molecular targets for development of promising therapeutics against human cancers that harbor activated STAT proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10550013     DOI: 10.1097/00001622-199911000-00010

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  39 in total

Review 1.  Protein kinases as therapeutic targets.

Authors:  R Sridhar; O Hanson-Painton; D R Cooper
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

2.  Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.

Authors:  Fengdong Cheng; Hongwei Wang; Pedro Horna; Zi Wang; Bijal Shah; Eva Sahakian; Karrune V Woan; Alejandro Villagra; Javier Pinilla-Ibarz; Said Sebti; Mitchell Smith; Jianguo Tao; Eduardo M Sotomayor
Journal:  Cancer Res       Date:  2012-06-22       Impact factor: 12.701

Review 3.  Suppressors of cytokine signaling in health and disease.

Authors:  Jane C Tan; Ralph Rabkin
Journal:  Pediatr Nephrol       Date:  2005-02-19       Impact factor: 3.714

4.  EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures.

Authors:  Ombretta Salvucci; Dragan Maric; Matina Economopoulou; Shuhei Sakakibara; Simone Merlin; Antonia Follenzi; Giovanna Tosato
Journal:  Blood       Date:  2009-05-01       Impact factor: 22.113

5.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis.

Authors:  T Bowman; M A Broome; D Sinibaldi; W Wharton; W J Pledger; J M Sedivy; R Irby; T Yeatman; S A Courtneidge; R Jove
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

6.  A novel mechanism of skin tumor promotion involving interferon-gamma (IFNγ)/signal transducer and activator of transcription-1 (Stat1) signaling.

Authors:  Ronald Bozeman; Erika L Abel; Everardo Macias; Tianyi Cheng; Linda Beltran; John DiGiovanni
Journal:  Mol Carcinog       Date:  2014-01-25       Impact factor: 4.784

7.  Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?

Authors:  Andrew Jarnicki; Tracy Putoczki; Matthias Ernst
Journal:  Cell Div       Date:  2010-05-17       Impact factor: 5.130

8.  Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells.

Authors:  Daniel R Premkumar; Esther P Jane; Naomi R Agostino; Joseph L Scialabba; Ian F Pollack
Journal:  J Carcinog       Date:  2010-07-14

9.  Heavy ion irradiation increases apoptosis and STAT-3 expression, led to the cells arrested at G2/M phase in human hepatoma SMMC-7721 cells.

Authors:  Jianxun Ma; Lanping Ye; Mingxu Da; Xiaopeng Wang
Journal:  Mol Cell Biochem       Date:  2009-03-13       Impact factor: 3.396

10.  Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Authors:  V Ramakrishnan; M Timm; J L Haug; T K Kimlinger; L E Wellik; T E Witzig; S V Rajkumar; A A Adjei; S Kumar
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.